Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GMI-1359 in HR+ Metastatic Breast Cancer
NCT04197999Phase 1Terminated
- Sponsor
- GlycoMimetics
- Start
- Nov 2019
- Primary completion
- Aug 2021
- Modality
- Bivalent/Multivalent Binders, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GMI-1359 in breast cancer, sponsored by GlycoMimetics. Primary endpoint: Dose-Limiting Toxicities up to 4 months. Started Nov 2019; status: terminated.
02
Drugs
GMI-1359
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04197999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04197999.